Rapid and cost-effective SNP detection method: Application of SmartAmp2 to pharmacogenomics research

Pharmacogenomics

Volumn 10, Issue 7, 2009, Pages 1187-1197

  Mitani, Yasumasa ^a,b   Lezhava, Alexander ^b   Sakurai, Aki ^b,c   Horikawa, Akina ^b,c   Nagakura, Makoto ^d   Hayashizaki, Yoshihide ^b   Ishikawa, Toshihisa ^c  

^a KK DNAFORM   (Japan)

^b RIKEN YOKOHAMA INSTITUTE   (Japan)

^c TOKYO INSTITUTE OF TECHNOLOGY   (Japan)

^d BioTec Co Ltd   (Japan)

Author keywords

ABCB1; ABCC11; CYP2C19; CYP2C9; Individualized medicine; MutS; Pharmacogenomics; SNP; UGT1A1; VKORC1

Indexed keywords

ABC TRANSPORTER; ABC TRANSPORTER C11; ADENINE; ARGININE; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; DNA; GLUCURONOSYLTRANSFERASE 1A1; GLYCINE; GLYCOPROTEIN P; GUANINE; IRINOTECAN; K RAS PROTEIN; MENADIONE EPOXIDE REDUCTASE; MULTIDRUG RESISTANCE PROTEIN 1; OXIDOREDUCTASE; PROTEIN MUTS; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DNA HYBRIDIZATION; DNA ISOLATION; DNA MICROARRAY; DRUG EFFICACY; DRUG HYDROLYSIS; DRUG LABELING; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; ETHNIC DIFFERENCE; FOOD AND DRUG ADMINISTRATION; GENE AMPLIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE MAP; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; INDIVIDUALIZATION; INTERMETHOD COMPARISON; LEUKOPENIA; LUNG CANCER; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MEDICAL RESEARCH; MOLECULAR MECHANICS; MUTATIONAL ANALYSIS; PANCREAS CANCER; PATIENT CARE; PHARMACOGENOMICS; POLYMERASE CHAIN REACTION; PROGNOSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SWEAT GLAND DISEASE; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT;

COST-BENEFIT ANALYSIS; HUMANS; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; TIME FACTORS;

EID: 70449482113     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.09.39     Document Type: Article

References (53)

1. Wilke RA, Lin DW, Roden DM et al.: Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat. Rev. Drug Discov. 6, 904-916 (2007). ■ Comprehensive review article addressing the current status of genotyping to prevent drug-induced serious adverse reactions.
2. Weiss ST, McLeod HL, Flockert DA et al.: Creating and evaluating genetic tests predictive of drug response. Nat. Rev. Drug Discov. 7, 568-574 (2008).
3. Sadee W: Drug therapy and personalized health care: pharmacogenomics in perspective. Pharm. Res. 25(12), 2713-2719 (2008).
4. Andersson T, Flockert DA, Goldstein DB et al.: Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin. Pharmacol. Ther. 78(6), 559-581 (2005). ■ Comprehensive overview on genetic polymorphisms of drug-metabolizing enzymes. (Pubitemid 41773633)
5. Miller RD, Phillips MS, Jo I et al.: High-density single-nucleotide polymorphism maps of the human genome. Genomics 86, 117-126 (2005). (Pubitemid 40917219)
6. Human Genome Sequencing Consortium: Finishing the euchromatic sequence of the human genome. Nature 431, 931-945 (2004).
7. Sachidanandam R, Weissman D, Schmidt SC et al.: A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409, 928-933 (2001). (Pubitemid 32165347)
8. Cusatis G, Sparreboom A: Pharmacogenomic importance of ABCG2. Pharmacogenomics 9(8), 1005-1009 (2008).
9. Ishikawa T, Tsuji A, Inui K et al.: The genetic polymorphism of drug transporters: functional ana lysis approaches. Pharmacogenomics 5(1), 67-99 (2004). (Pubitemid 38088481)
10. Salerno R, Lesko LJ: Pharmacogenomics in drug development and regulatory decision-making: the genomic data submission. Pharmacogenomics 5(1), 25-30 (2004). ■ Provides US FDA draft guidance for volunteer submission of pharmacogenomic data. (Pubitemid 38088478)
11. Salerno R, Lesko LJ: Pharmacogenomic data: FDA voluntary and required submission guidance. Pharmacogenomics 5(5), 503-505 (2004). ■ Provides US FDA draft guidance for volunteer submission of pharmacogenomic data. (Pubitemid 39023066)
12. Leighton JK, Degeorge J, Jacobson-Kram D et al.: Pharmacogenomic data submission to FDA: non-clinical case studies. Pharmacogenomics 5(5), 507-511 (2004). ■ Provides US FDA draft guidance for volunteer submission of pharmacogenomic data. (Pubitemid 39023067)
13. Ruano G, Collins JM, Dorner AJ et al.: Pharmacogenomic data submission to the FDA: clinical pharmacology case studies. Pharmacogenomics 5(5), 513-517 (2004). ■ Provides US FDA draft guidance for volunteer submission of pharmacogenomic data. (Pubitemid 39023068)
14. Trepiccho WL, Williams GA, Essayan D et al.: Pharmacogenomic data submission to the FDA: clinical case studies. Pharmacogenomics 5(1), 519-524 (2004). ■ Provides US FDA draft guidance for volunteer submission of pharmacogenomic data. (Pubitemid 39023069)
15. Frueh FW, Amur S, Mummaneni P et al.: Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: prevalence of related drug use. Pharmacotherapy 28(8), 992-998 (2008).
16. Lesko LJ: The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84(3), 301-303 (2008).
17. Kim MJ, Huang SM, Meyer UA et al.: A regulatory science perspective on warfarin therapy: a pharmacogenetic opportunity. J. Clin. Pharmacol. 49(2), 138-146 (2009). ■ Provides information on the US FDA perspective on pharmacogenetics-based warfarin dosing.
18. Fan JB, Chen X, Halushka MK et al.: Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res. 10, 853-860 (2000). (Pubitemid 30433358)
19. Saperstein DA, Nickerson JM: Restriction fragment length polymorphism ana lysis using PCR coupled to restriction digests. Biotechniques 10(4), 488-489 (1991).
20. Heim M, Meyer UA: Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification. Lancet 336, 529-532 (1990). (Pubitemid 20278099)
21. See D, Kanazin V, Talbert H, Blake T: Electrophoretic detection of single-nucleotide polymorphisms. Biotechniques 28, 710-714 (2000).
22. Griffin TJ, Smith LM: Single nucleotide polymorphism ana lysis by MALDI-TOF mass spectrometry. Trends Biotechnol. 18, 77-84 (2000).
23. Ross P, Hall L, Smirnov I, Haff L: High level multiplex genotyping by MALDI-TOF mass spectrometry. Nat. Biotechnol. 16, 1347-1351 (1998). (Pubitemid 28547446)
24. Bassler HA, Flood SJ, Livak KJ et al.: Use of a fluorogenic probe in a PCR-based assay for the detection of Listeria monocytogenes. Appl. Environ. Microbiol. 61(10), 3724-3728 (1995).
25. Livak KJ: Allelic discrimination using fluorogenic probes and 5′ nuclease assay. Genet Anal. 14(5-6), 143-149 (1999).
26. Lymichev V, Mast AL, Hall JG et al.: Polymorphism identification and quantitative detection of genomic DNA by invasive cleavage of oligonucleotide probes. Nat. Biotechnol. 17(3), 292-296 (1999).
27. Mitani Y, Lezhava A, Kawai Y et al.: Rapid SNP diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat. Methods 4(3), 257-262 (2007). ■ First original article presenting the SmartAmp2 method for SNP typing. This article describes its molecular mechanism and clinical applications. (Pubitemid 46358877)
28. Rozen S, Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol. Biol. 132, 365-386 (2000).
29. Kaminsky LS, Zhang ZY: Human P450 metabolism of warfarin. Pharmacol. Ther. 73, 67-74 (1997).
30. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ, Vandenbrouck JP, Briet E: Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. 333, 11-17 (1995).
31. Fihn SD, McDonell M, Martin D et al.: Risk factors for complications of chronic anticoagulation. Ann. Intem. Med. 118, 511-520 (1993).
32. Aomori T, Yamamoto K, Oguchi-Katayama A et al.: Rapid SNP detection of the cytochrome P-450 (CYP) 2C9 and the vitamin K oxide reductase (VKORC1) gene for the warfarin dose adjustment by Smart-Amplification process version 2. Clin. Chem. 55, 804-812 (2009).
33. Ando Y, Saka H, Ando M et al.: Polymorphisms of UDP- glucuronosyltransferase gene and irinotecan adverse reactions: a pharmacogenetic ana lysis. Cancer Res. 60, 6921-6926 (2000). (Pubitemid 32059164)
34. Ando Y, Hasegawa Y: Clinical pharmacogenetics of irinotecan (CPT-11). Drug Metab. Rev. 37, 565-574 (2005). ■ Comprehensive review article addressing the genetic polymorphisms of UDPglucuronosyltransferase gene and irinotecan-induced adverse reactions.
35. Rouits E, Boisdron-Celle M, Dumont A, Guerin O, Morel A, Gamelin E: Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients. Clin. Cancer Res. 10, 5151-5159 (2004).
36. Iyer L, Das S, Janisch L et al.: UGT1A1*28 polymorphism as a determinant of irinotecan disposition and adverse reactions. Pharmacogenomics J. 2, 43-47 (2002).
37. Innocenti F, Undevia SD, Iyer L et al.: Genetic variants in the UDPglucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J. Clin. Oncol. 22, 1382-1388 (2004).
38. Marcuello E, Altes A, Menoyo A et al.: UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer 91, 678-682 (2004). (Pubitemid 39141623)
39. Kitagawa C, Ando M, Ando Y et al.: Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genomics 15, 35-41 (2005). (Pubitemid 43205525)
40. Hasegawa Y, Ando Y, Ando M, Hashimoto N, Imaizumi K, Shimokata K: Pharmacogenetic approach for cancer treatment-tailored medicine in practice. Ann. NY Acad. Sci. 1086, 223-232 (2006). (Pubitemid 47084388)
41. Innocenti F, Grimsley C, Das S et al.: Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groups. Pharmacogenetics 12, 725-733 (2002). (Pubitemid 36054939)
42. Watanabe J, Mitani Y, Kawai Y et al.: Complete suppression of background amplification using competitive probe in a Smart-Amplification Process assay for microsatellite polymorphism genotyping of UGT1A1*28. Biotechniques 43, 479-484, (2007). ■ Original article presenting SmartAmp2 method-based genotyping of UGT1A1*28.
43. Tatsumi K, Mitani Y, Watanabe J et al.: Rapid screening assay for KRAS mutations by the modified smart amplification process. J. Mol. Diagn. 10(6), 520-526 (2008). ■ Original article presenting SmartAmp2 method-based detection of K-ras mutations.
44. Leschzinger GD, Andrew T, Pirmohamed M, Johnson MR: ABCB1 genotype and PGP expression, function and therapeutic drug response: a critical review and recommendations for future research. Pharmacogenomics J. 7, 154-179 (2007). ■ Comprehensive review article addressing the genetic polymorphisms of ABCB1 (P-glycoprotein/MDR1) and their impact on therapeutic drug response.
45. Sakurai A, Onishi Y, Hirano H et al.: Quantitative SAR ana lysis and molecular dynamic simulation to functionally validate nonsynonymous polymorphisms of human ABC transporter ABCB1. Biochemistry 46(26), 7678-7693 (2007).
46. Hüebner C, Petermann I, Browning BL et al.: Triallelic single nucletotide polymorphisms and genotyping error in genetic epidemiology studies: MDR1 (ABCB1) G2677/T/A as an example. Cancer Epidemiol. Biomarkers. Prev. 16(6), 1185-1192 (2007). (Pubitemid 46984957)
47. Borst P, Elferink RO: Mammalian ABC transporters in health and disease. Annu. Rev. Biochem. 71, 537-592 (2002). (Pubitemid 34800230)
48. Yoshiura K, Kinoshita A, Ishida T et al.: A SNP in the ABCC11 gene is the determinant of human earwax type. Nat. Genet. 38(3), 324-330 (2006). ■ Original paper addressing a unique SNP in ABCC11 (MRP8) and its physiological impact.
49. Toyoda Y, Sakurai A, Mitani Y et al.: Earwax, osmidrosis, and breast cancer: why does one SNP (538G>A) in the human ABC transporter ABCC11 gene determine earwax type? FASEB J. 23(6), 2001-2013 (2009).
50. Guidance for Industry Pharmacogenomic Data Submissions (March 2005) www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/ Guidances/ucm079849.pdf
51. US FDA 'Guidance for Industry: Pharmacogenomic Data Submissions'. The latest information issued in March 2005 www.fda.gov/bbs/topics/news/2007/ new01684.html
52. The Smart Amplification process www.smapdna.com
53. DNAForm: the precision gene technologies www.dnaform.jp